Both estrogen and testosterone are integral for cardiometabolic health in both men and women, yet little is known about the cardiometabolic responses to testosterone in women and estrogen in males. This information is critical for optimizing health in aging male and female patients as endogenous hormones decline. Our preliminary data in mice shows vascular damage induced by testosterone in females and estrogen in males, indicating a critical need to fully characterize their impact on cardiometabolic health in both sexes. Our novel therapeutic strategy to protect the vasculature while preserving metabolic benefits of these hormones is co-treatment with a non-classical estrogen receptor agonist. Upon successful completion, this proposal will uncover novel information to optimize cardiometabolic health in patients taking hormone therapy.
